Every story stays here. Filter by topic, search older headlines, and save favorites to your member record. Educational notes only — not medical advice.
Study (observational; one week of wrist tracking). A Harvard Heart Letter brief on 2 October 2026 describes a paper published online on 8 September 2026 in the British Journal of Sports Medicine. Researchers used tracker data from 64,743 adults in the United Kingdom, average age 62. Over about eight years there were 1,697 deaths, 502 of them from cardiovascular disease. Pace was the average steps per minute across each person’s 30 highest-activity minutes, which did not have to be consecutive. Compared with people who took fewer than 5,000 steps a day at about 45 steps per minute, people under 5,000 steps who walked faster had a substantially lower risk of cardiovascular and other deaths, similar to people who took 5,000 to 7,500 steps at a slower pace. The lowest death rates in the step groups were at 7,500 to 10,000 steps a day. The authors call a brisk 90 to 100 steps per minute for 30 minutes a day a promising target, and say people with less time or ability can mix step count and speed. The brief does not give a hazard ratio. This is not a randomized walking program, and one week of tracking does not prove that speeding up caused the lower death rate. The brief does not split results by sex. Educational notes. This is not a training prescription.
Study (randomized, double-blind, placebo-controlled). The STAREE trial abstract in the New England Journal of Medicine (2026; 395(13):1259-1272; doi 10.1056/NEJMoa2607314; epub 29 August 2026; issue date 1 October 2026; PubMed 42670961) reports community-dwelling adults at least 70 years old with no history of cardiovascular disease, diabetes, or dementia, randomized to atorvastatin 40 mg once daily or placebo. Monash’s news account called it a trial of nearly 10,000 people, run with general practices across Australia and presented at the European Society of Cardiology Congress on 29 August 2026. After a median 5.9 years, a primary cardiovascular event occurred in 297 people on atorvastatin (10.9 per 1,000 person-years) and 412 on placebo (15.5 per 1,000 person-years); hazard ratio 0.70; 95% CI 0.61 to 0.82; P<0.001. Death from any cause, dementia, or persistent physical disability occurred in 637 versus 676 (21.6 versus 23.0 per 1,000 person-years); hazard ratio 0.94; 95% CI 0.84 to 1.05; P=0.25. Serious adverse events were 131 (2.7%) versus 129 (2.7%). Musculoskeletal, hepatobiliary, and diabetes-related adverse events were more common on atorvastatin. The abstract does not give a sex split. ClinicalTrials.gov NCT02099123. Atorvastatin is a prescription statin. Starting or stopping it is a clinician decision. Educational notes. This is not medical advice and not a substitute for a prescribed medicine.
Study (human skin biopsies). Rachel Neale, David Whiteman, and colleagues at QIMR Berghofer describe the Low-Dose UV Study; ScienceDaily carried it on 1 October 2026. Fifty-eight people with light to olive skin had a patch of back skin exposed to lower-intensity ultraviolet (such as mid-morning) and higher-intensity ultraviolet (such as around noon) across several days, matched so the total dose could be compared. Biopsies showed DNA damage and a rise in p53, a protein that increases when skin cells are stressed, even when the dose was too small to turn the skin pink. Delivering the same dose slowly or quickly did not change that finding. Whiteman said the damage is not cancer itself; repeated incidental doses can add mutations over years. The release says sunlight also supports vitamin D and is a complete carcinogen, and that current advice is sun protection when the UV index is 3 or higher. The release names the paper as being in Photochemistry and Photobiology. The automatic journal line on the ScienceDaily page points at a different Nature Communications paper about nevus count, so that DOI is not used here. The release does not give ages or a sex split. Educational notes. This is not a vitamin D study and not advice to avoid daylight entirely.
Study (computational reanalysis, not a new patient cohort). Dmitry Pshezhetskiy at the University of East Anglia and colleagues, with Oxford BioDynamics, report in the Journal of Translational Medicine (2026; 24(1); doi 10.1186/s12967-026-08874-9; ScienceDaily 1 October 2026). They used the EpiSwitch Orion platform to predict three-dimensional DNA contacts. Published genome-wide association data for long Covid, PTSD, rheumatoid arthritis, and multiple sclerosis were combined with earlier 3D-genome data from people with ME/CFS. Individual genes barely overlapped. Network analysis connected the conditions through immune and inflammatory signaling, mitochondrial energy production, metabolic regulation, stress responses, and neuroendocrine signaling. Hub genes are candidates only. LAG3, tied to T-cell exhaustion, was highlighted for ME/CFS and still needs confirmation. The authors say a blood test for these signatures is not ready for clinical use. London School of Hygiene and Tropical Medicine and Cornwall Partnership NHS Foundation Trust collaborated. Educational notes. This does not diagnose fatigue, and it is not a treatment.
Study (rats). Scott Rector and colleagues at the University of Missouri School of Medicine report in Cell Reports (2026; DOI 10.1016/j.celrep.2026.117416; MedicalXpress 1 October 2026), from the MoTrPAC endurance-exercise dataset. Female rats made more proteins in the Krebs cycle, the mitochondrial pathway that produces cellular energy. Male rats more often remodeled existing proteins by a chemical change that triggers that cycle. Rector said neither pattern is a better adaptation. In both sexes, training lined up with less liver fat, better cholesterol use and disposal, and fewer fibrosis markers. Males appeared to expel more cholesterol than females. The release does not give the number of animals. The authors say the sex difference might later matter for metabolic dysfunction-associated steatotic liver disease, and that why the pathways differ is still unknown. These are rat findings, not a human training result. Educational notes.
Study (cross-sectional imaging). The REACT study, presented in a Hot Line session at ESC Congress 2026 on 29 August and published in the New England Journal of Medicine, was carried by ScienceDaily on 1 October 2026. Researchers in Denmark and Spain imaged 16,808 adults ages 18 to 70 (mean age 45) with no known atherosclerotic cardiovascular disease, balanced by sex within each age decade. Three-dimensional ultrasound covered carotid and femoral arteries; coronary arteries were imaged by CT. Plaque was present in 57.1%. About 1 in 13 people ages 18 to 29 had plaque in at least one territory. About 9 in 10 people ages 60 to 70 had plaque. Prevalence rose earlier in men, by about 5 to 10 years, while women showed a steeper rise in midlife around the usual age of menopause. Most people with coronary plaque also had plaque in the neck or leg arteries. This is a snapshot of who already has plaque, not a test of a prevention program. Educational notes.
Study (human tissue models, postmortem brain, and mice). Joel W. Blanchard and colleagues at the Icahn School of Medicine at Mount Sinai report two papers carried by ScienceDaily on 1 October 2026. In Cell (24 September 2026; doi 10.1016/j.cell.2026.08.058), Braxton R. Schuldt and colleagues mapped gene activity in human brain blood-vessel cells and found that APOE4 pushed pericytes toward scar-making myofibroblast-like cells, with more fibrosis and amyloid around vessels. Blocking TGF-beta signaling restored pericyte coverage and reduced that fibrosis and amyloid, including in aged APOE4 mice. In Cell Stem Cell (2026; 33(9):1459; doi 10.1016/j.stem.2026.08.001), Louise Mesentier-Louro and colleagues used stem-cell “miBrain” tissue. APOE4 tissue built up more alpha-synuclein. Cholesterol piled up in astrocytes and weakened lysosomal cleanup, and the protein spread to neurons. These are laboratory and animal findings, not a treatment tested in people with Alzheimer disease. Educational notes.
Study (small crossover pilot). Nyasha Chagwedera, Andrew Krystal, and colleagues at UC San Francisco report in JAMA Psychiatry (23 September 2026; doi 10.1001/jamapsychiatry.2026.2320; ScienceDaily 1 October 2026). Twenty adults with depression (average age 44; 70% women; 14 also had anxiety; high BMI and at least one metabolic disorder) spent four weeks on their usual eating pattern and four weeks choosing foods low in ultra-processed products, with guidance from the team. They cut ultra-processed intake by more than 85%. Depression scores improved by a moderate to large amount on three measures. Anxiety scores improved modestly. The authors describe a possible leaky-gut and low-grade inflammation path; this pilot did not prove that path. Phase 2 enrollment is planned for 2028. Twenty people cannot show that avoiding packaged food treats depression. Educational notes. This is not a diet prescription.
Study (12-week trial; journal supplement issue). Richard Kreider and colleagues at Texas A&M report in the Journal of the International Society of Sports Nutrition (2026; 23 supplement 1; doi 10.1080/15502783.2026.2716273; Texas A&M 18 September 2026; ScienceDaily 29 September 2026). Sixty-four healthy adults ages 45 to 65 finished. People chose whether to join a resistance-plus-aerobic plan three times a week plus a modest calorie deficit, or to stay out of that plan, and were then randomized to 10 grams of creatine monohydrate or placebo daily. In the no-plan group, creatine tracked about 2.4 pounds (1.1 kg) more lean tissue and higher leg-press and bench-press strength. In the plan group, creatine tracked nearly 3 pounds (1.4 kg) more lean tissue and a larger drop in body-fat percentage, while placebo showed little lean-tissue change, plus greater strength and longer time to exhaustion. Aerobic capacity did not rise beyond the plan itself. Choosing the plan was not randomized. The citation is a supplement issue, so this may be a meeting report rather than a full paper. A 2025 review by Kreider’s group of 685 trials found no significant difference in side-effect rates versus placebo; that is not a personal safety clearance. Educational notes. This is not a reason to start a 10-gram scoop for weight loss.
Alzheimer’s disease (AD) represents one of the most prevalent neurodegenerative disorders without approved disease-modifying therapies. A major contributing factor is that, for decades, drug development has focused almost exclusively on repairing or removing lesions within the brain itself. Yet a growing body of work now points to AD as a systemic disorder, rooted in a breakdown of whole-body Aβ homeostasis. Neverthe
Study (pooled intervention analysis). Raghav Sehgal and colleagues at Yale report in Nature Medicine (doi 10.1038/s41591-026-04562-9; healthmedicinet 29 September 2026) a re-analysis of 51 human intervention studies with more than 110 DNA-methylation biomarkers, including 16 major epigenetic clocks. They grouped the work into clinic-directed products, lifestyle programs, store-bought products, and procedures. Programs that combined a healthy eating pattern (Mediterranean, lower-carbohydrate, or lower-fat) with regular movement consistently lowered epigenetic-age estimates. Clinic-directed metabolic products, including metformin and semaglutide, and anti-TNF biologics that target an immune protein tied to inflammation, produced the largest average clock drops. Store-bought products and some procedures did not lower the clocks in this pool. Newer clocks moved more than older ones, and people who already had disease showed larger biomarker shifts than healthy volunteers. Clocks are not proof of longer life. Educational notes. Educational supplement parallel (not a replacement): When longevity headlines discuss metformin, people often also research berberine. That is an off-label / curiosity parallel, not a recommendation to take berberine instead of metformin. Human longevity outcome data for both are limited; disease-use of metformin is clinician-prescribed. Weakly evidenced as an anti-aging product. Store: /store/berberine. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (case-control imaging). Shile Qi of Nanjing University of Aeronautics and Astronautics and colleagues, including Vince D. Calhoun, report in PLOS Medicine (doi 10.1371/journal.pmed.1004860; ScienceDaily 29 September 2026) a predictive age difference (PAD) analysis: brain age estimated from structural MRI minus calendar age. They used 45,900 control scans and 2,698 scans from people with ADHD, autism, alcohol or tobacco addiction, Alzheimer disease, mild cognitive impairment, schizophrenia, bipolar disorder, or major depression. Alzheimer disease and mild cognitive impairment showed the largest positive PAD. Addiction and several psychiatric diagnoses also showed higher PAD. ADHD and autism showed no overall PAD difference versus controls. The prefrontal cortex showed higher PAD across several diagnoses. Psychiatric diagnoses lined up with frontal and temporal PAD; dementia with frontal and occipital PAD; addiction with default-mode, salience, putamen, and thalamus PAD. The work is correlational and does not show that a diagnosis causes a brain to age faster. Educational notes.
VitaLonga is an educational longevity resource, not a pharmacy, clinic, or doctor. Content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease (DSHEA). Supplements can interact with medications and are not appropriate in every pregnancy or health condition. Consult a licensed clinician, especially if you take medications, are pregnant or nursing, or have a diagnosed condition.
